United Therapeutics (UTHR) Net Margin (2009 - 2026)

United Therapeutics has disclosed Net Margin across 18 years of filings, most recently posting 35.18% for Q1 2026.

• Net Margin for Q1 2026 came in at 35.18%, down 538.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 40.61% (up 18.0% YoY), and the FY2025 annual result was 41.94%, up 40.0% from the prior year.
• Net Margin came in at 35.18% for Q1 2026 at United Therapeutics, down from 46.1% in the prior quarter.
• In the past five years, Net Margin ranged from a high of 51.94% in Q1 2022 to a low of 24.84% in Q2 2022.
• The 5-year median for Net Margin is 41.27% (2024), against an average of 40.56%.
• Peak annual rise in Net Margin reached 4447 bps in 2022, while the deepest fall reached 1381 bps in 2022.
• United Therapeutics' Net Margin stood at 26.88% in 2022, then surged by 31 bps to 35.32% in 2023, then advanced by 16 bps to 40.94% in 2024, then gained by 13 bps to 46.1% in 2025, then slipped by 24 bps to 35.18% in 2026.
• The last three Net Margin figures came in at 35.18% (Q1 2026), 46.1% (Q4 2025), and 42.36% (Q3 2025), per Business Quant data.